

PRODUCT INFORMATION



CP 671,305

Item No. 26743

CAS Registry No.: 445295-04-5
Formal Name: (2R)-2-[4-[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-fluorophenoxy]-propanoic acid

MF: C₂₃H₁₉FN₂O₇

FW: 454.4


Purity: ≥98%

UV/Vis.: λ_{max}: 279 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CP 671,305 is supplied as a crystalline solid. A stock solution may be made by dissolving the CP 671,305 in the solvent of choice, which should be purged with an inert gas. CP 671,305 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of CP 671,305 in these solvents is approximately 3, 25, and 50 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of CP 671,305 can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of CP 671,305 in PBS, pH 7.2, is approximately 2 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

CP 671,305 is a potent inhibitor of phosphodiesterase 4D (PDE4D; IC₅₀ = 3 nM).¹ It is selective for PDE4D over PDE4A, -B, and -C (IC₅₀s = 310, 287, and 3,858 nM, respectively), as well as over PDE1-3 and 5 (IC₅₀s = >5,000 nM for all). CP 671,305 inhibits release of leukotriene E₄ (LTE₄; Item No. 20410) from eosinophils (IC₅₀ = 52 nM) and LTB₄ (Item No. 20110) from neutrophils (IC₅₀ = 106 nM). *In vivo*, CP 671,305 inhibits antigen-induced pulmonary eosinophil influx in cynomolgus monkeys in a dose-dependent manner.

Reference

1. Kalgutkar, A.S., Choo, E., Taylor, T.J., *et al.* Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species. *Xenobiotica* **34**(8), 755-770 (2004).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/03/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM